Central question is no longer whether GLP works, but how to optimize and sustain its effects

Obesity field is evolving

Obesity has risen dramatically over recent decades, emerging as a major global public health challenge that increases both the risk and severity of cardiometabolic, infectious, and malignant diseases. According to the Global Burden of Disease Study 2021, approximately 2.11 billion adults were living with overweight or obesity, with projections suggesting that nearly two-thirds of adults over 25 years will be affected by 2050, including one-third with obesity. Despite this burden, pharmacological treatment remains markedly underutilized. Although more than half of adults meet eligibility criteria for anti-obesity medications, only a small fraction receive them—contrasting sharply with treatment patterns for conditions such as type 2 diabetes mellitus and hypertension.